BY THE NUMBERSIN THE NEWS TODAYTwitter put a “public curiosity discover” on an early Friday tweet from the president, saying the publish violated the platform’s guidelines concerning the glorifying of violence. The Trump tweet in query targets the protests in Minneapolis over the loss of life of George Floyd. On Thursday, the president signed an govt order on social media “censorship,” two days after Twitter put a fact-check label on different Trump tweets. (CNBC)Scientific trials of medication, remedies and vaccines unrelated to Covid-19 will probably face delays going ahead because the company focuses its sources on addressing the virus, former Meals and Drug Administration Commissioner Dr. Scott Gottlieb advised CNBC on Friday.The European Union will conduct an accelerated evaluation of Gilead Sciences’ (GILD) remdesivir as a possible remedy for Covid-19, mentioned the European Medicines Company. The U.S. Meals and Drug Administration granted an emergency use authorization for the usage of remdesivir to deal with Covid-19 sufferers earlier this month. (Reuters)Tesla (TSLA) confirms that CEO Elon Musk, who known as coronavirus lockdowns “fascist” and reopened a California meeting plant in defiance of an area order, earned the primary tranche of his large incentive payout worth about $775 million based mostly on Thursday’s shut. (CNBC)* GM to extend North American manufacturing of crossover, pickup vehicles subsequent week (Reuters)Tyson Meals (TSN) will briefly shut its Storm Lake, Iowa, pork processing plant, after 555 staff, or practically 1 / 4 of the power’s workforce, examined optimistic for the coronavirus. Tyson mentioned it plans to renew operations subsequent week after extra deep cleansing and sanitizing of the plant. (Reuters)Costco (COST) gross sales grew in its fiscal third quarter ending Might 10, because the wholesale large benefited from clients shopping for packs of bathroom paper, instances of bottled water and bulk grocery gadgets in the course of the coronavirus pandemic. However that development was constrained by state stay-at-home orders. (CNBC)Huge Heaps (BIG) is the newest low cost retailer to report a robust quarter in the course of the pandemic, incomes an adjusted $1.26 per share in contrast with a 40 cent estimate. Income exceeded forecasts as effectively, with same-store gross sales leaping 10.3% in contrast with a 1% estimate.Nordstrom (JWN) misplaced $3.33 per share for its newest quarter, greater than triple than consensus estimate of a $1.07 per share loss. The retailer’s income additionally missed estimates, as nationwide lockdowns shut its shops. General gross sales have been down virtually 40% in the course of the quarter.STOCKS TO WATCHWilliams-Sonoma (WSM) reported adjusted quarterly earnings of 74 cents per share, hovering previous the consensus estimate of three cents, whereas income was additionally above forecasts. The housewares retailer was helped by a surge in on-line gross sales, with family necessities in demand amid widespread sheltering at residence.Ulta Magnificence (ULTA) misplaced $1.39 per share for its newest quarter, shocking analysts who had predicted a 48 cents per share revenue. Income missed estimates as effectively, because the cosmetics retailer’s comparable retailer gross sales sank 35%.Salesforce (CRM) beat estimates by a penny with adjusted quarterly earnings of 70 cents per share, with the enterprise software program firm’s income barely above estimates as effectively. Nonetheless, the corporate reduce its annual revenue and income forecast, due partly to permitting purchasers to defer funds in addition to paying one-time commissions to its gross sales workforce.Dell Applied sciences (DELL) reported adjusted quarterly earnings of $1.34 per share, beating the consensus estimate of 92 cents, with income beating forecasts as effectively. Dell benefited from workstation purchases by firms transferring extra staff to home-based work.Eli Lilly (LLY) received FDA approval for its radioactive agent that may detect a key marker for Alzheimer’s illness. AstraZeneca (AZN) reported success in a part Three trial involving the usage of its Tagrisso lung most cancers drug to deal with in EGFR (epidermal development issue receptor) mutated lung most cancers.